

ABSTRACT for Nectin Therapeutics Presentation

Questions for categories: Biotech/Pharma

○ **Investment Rational**

Nectin Therapeutics is a biotechnology company developing next-generation immun-oncology (IO) therapies that address major escape mechanisms of current IO therapies. Led by a world-class team. Nectin Therapeutics is a venture-backed, funded by aMoon Fund, Peregrine Ventures, Integra Holdings and the Cancer Focus Fund. It's lead asset is planned to start a first in human study in Q2 2022.

○ **Business Strategy**

Nectin Therapeutics is planning to enter Phase 1 for its lead First-in-Class Anti-PVR candidate at the MD Anderson Cancer Center later this year with data readouts beginning in 2023.

The company plans to progress additional portfolio assets into the clinic in 2023 and 2024.

○ **Core Technology**

The company's research leverages unique insights into the Nectin pathway to address resistance to approved IO therapies through a differentiated pipeline of novel antibodies and antibody-drug-conjugates.

Our assets demonstrate unprecedented preclinical efficacy, supported by strong scientific rational and a favorable safety profile. Our portfolio therapies are being studied as mono therapy and in various combinations including unique internal pipeline synergies.

○ **Product Profile/Pipeline**

- Anti-PVR (NTX1088): First-in-Class blocking mAb, initiating FIH trial in Q2 2022
- Anti CD112R (NTX2R13): Best-in-class mAb. IND planned for 2023
- Anti-PVR ADC (NTX8090): First-in-Class ADC candidate against solid tumors
- NTX 1107 ADC (undisclosed): First-in-Class ADC candidate against solid and hematological tumors
- Anti-Nectin 4 ADC (NTX1105): A differentiated Best-in-Class ADC candidate demonstrating superior therapeutic index

○ **What's Next?**

The company has recently entered a clinical development partnership with MD Anderson Cancer Center and the Cancer Focus Fund to initiate its first clinical trial. In parallel, the company plans to continue its pre-clinical development activities for its other assets. The company plans to continue and strengthen the teams both in its Jerusalem labs and at the US headquarters.